Transfer of Nicox’s shares to Euronext Growth Paris effective on
April 28, 2023
Press Release
Transfer of Nicox’s shares to Euronext Growth
Paris effective on April 28, 2023
April 26, 2023 – release at 9:00 am CETSophia Antipolis,
France
Nicox SA (Euronext Paris:
FR0013018124, COX), an international ophthalmology company, today
announced that the transfer of the listing of the securities issued
by the Company from the Euronext Paris regulated market
(compartment C) to the Euronext Growth Paris multilateral trading
facility (the “Transfer”), will be effective as from the trading
session of April 28, 2023.
The application for the Transfer was approved by
the Euronext Listing Board on April 24, 2023.
As of April 28, 2023, the new mnemonic code of
Nicox’s shares will be ALCOX. The ISIN code remains unchanged:
FR0013018124.
This operation aims to allow the Company to have
its securities admitted to trading on a market more commensurate
with its size and market capitalization. Indeed, the Transfer to
Euronext Growth enables the Company to reduce its obligations and
constraints and, as a result, reduce the costs associated with its
listing, while maintaining the shares’ tradability on a financial
market.
The Company will continue to provide accurate,
precise and truthful information, by disclosing any privileged
information concerning the Company to the public, in accordance
with the European Regulation on Market Abuse (“MAR”). The
provisions of the MAR Regulation will also remain fully applicable
to the Company, with respect to the disclosure of transfers of
securities by directors.
The Information Document relating to the
Transfer is available on the Company's website www.nicox.com, in
the Investors section.
The Company is assisted by Bryan, Garnier &
Co. as Listing Sponsor in connection with the Transfer.
Definitive timetable for the transfer of listing
market
Date |
Operation |
April 26, 2023 |
Publication of a Euronext notice announcing the delisting of
Nicox’s shares from Euronext ParisPublication of a Euronext notice
announcing the listing of Nicox’s shares to Euronext Growth
ParisDissemination of a press release by the Company and online
publication of the Information Document on the Company's and
Euronext’s website |
April 28, 2023 before market opening |
Delisting of the Company's shares from the Euronext Paris regulated
market and admission of the Company's shares to the multilateral
trading facility Euronext Growth Paris |
About Nicox
Nicox SA is an international ophthalmology
company developing innovative solutions to help maintain vision and
improve ocular health. Nicox’s lead program in clinical development
is NCX 470, a novel nitric oxide-donating bimatoprost, for lowering
intraocular pressure in patients with open-angle glaucoma or ocular
hypertension. The company is also conducting research on NCX 1728,
a nitric oxide-donating phosphodiesterase 5 inhibitor, in retinal
conditions. NCX 4251, a novel, patented, ophthalmic suspension of
fluticasone propionate nanocrystals for topical ocular application
for dry eye disease, is being developed by Ocumension Therapeutics
in China under an exclusive license agreement and is available for
partnering elsewhere. Nicox generates revenue from 2 out-licensed
products; VYZULTA® in glaucoma, and ZERVIATE® in allergic
conjunctivitis, licensed in multiple geographies, including to
Eyevance Pharmaceuticals, LLC (a wholly-owned subsidiary of Santen
Pharmaceutical Co., Ltd.), in the U.S. and Ocumension Therapeutics
in the Chinese and in the majority of Southeast Asian
markets.
Nicox, headquartered in Sophia Antipolis,
France, is listed on Euronext Paris (Compartiment C: Mid
Caps;Ticker symbol: COX) and is part of the CAC Healthcare
index.
For more information on Nicox, its products or pipeline, please
visit: www.nicox.com.
Analyst coverage
Bryan, Garnier & Co
Eric
Yoo Paris,
FranceEdison Investment
Research Pooya
Hemami London,
UKH.C. Wainwright &
Co Yi
Chen New York,
U.S.Kepler
Cheuvreux Arsene
Guekam Paris,
France
The views expressed by analysts in their
coverage of Nicox are those of the author and do not reflect the
views of Nicox. Additionally, the information contained in their
reports may not be correct or current. Nicox disavows any
obligation to correct or to update the information contained in
analyst reports.
NicoxGavin SpencerExecutive Vice President,
Chief Business Officer& Head of Corporate Development T +33
(0)4 97 24 53 00communications@nicox.com
Forward-Looking Statements
The information contained in this document may
be modified without prior notice. This information includes
forward-looking statements. Such forward-looking statements are not
guarantees of future performance. These statements are based on
current expectations or beliefs of the management of Nicox S.A. and
are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements. Nicox S.A. and its affiliates,
directors, officers, employees, advisers or agents, do not
undertake, nor do they have any obligation, to provide updates or
to revise any forward-looking statements.
Risks factors which are likely to have a
material effect on Nicox’s business are presented in the 3rd
chapter of the ‘Document d’enregistrement universel, rapport
financier annuel et rapport de gestion 2021’ filed with the French
Autorité des Marchés Financiers (AMF) on April 29, 2022, in its
first amendment filed with the AMF on May 19, 2022, in the 2nd
chapter of its second amendment filed with the AMF on November 22,
2022 and in the 2nd chapter of the Securities note filed with the
AMF on November 22, 2022 which are available on Nicox’s website
(www.nicox.com)
Nicox S.A.Drakkar 2Bât D, 2405 route des
Dolines06560 Valbonne, FranceT +33 (0)4 97 24 53 00F +33 (0)4 97 24
53 99
- EN_EuronextGrowth Transfer & Listing PR_20230426_F
Nicox (LSE:0RCQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nicox (LSE:0RCQ)
Historical Stock Chart
From Apr 2023 to Apr 2024